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To the Editor—The guiding principles of sound
drug formulary system decisions, as endorsed by the
Academy of Managed Care Pharmacy, the Ameri-
can Medical Association, the US Pharmacopeia, and
other professional organizations are based “on sci-
entiﬁc and economic considerations that achieve
appropriate, safe, and cost-effective drug therapy”
[1]. There is a natural hierarchy to the judgments
that must be made. First, what are the magnitude
and balance of clinical beneﬁts and risks for a new
drug? Second, what are the relative clinical beneﬁts
and risks of a new therapy compared to existing
treatments? Third, what is the estimated economic
impact of the new versus existing therapies? The
ﬁrst two questions should be made within the
context of an evidence-based medicine framework.
The third question is made within a ﬁnancial and
economic framework.
Recently, the Academy of Managed Care Phar-
macy (AMCP) has promulgated a format for for-
mulary submissions, one of whose goals is to make
transparent the assumptions and evidence that are
critical to decisions. The format also standardizes
information requirements and provides a template
for formalizing analyses that estimate the potential
impact on both a health plan and its enrolled
patient population. “AMCP’s format has the poten-
tial to move managed care away from the pharmacy
silo-budgeting approach typically utilized for for-
mulary decisions to a total cost and health-impact
approach to health care delivery” [2]. While one
might expect that support for this format would be
similar to that for “mom and apple pie,” this has
not, as yet, been the case [3].
However, as it gains greater acceptance, those
who attempt to rigorously use the AMCP dossier
approach will encounter additional challenges. This
arises from the uncertainty inherent in the ques-
tions that formulary committees must answer, 
particularly if they adhere to the principles of 
evidence-based medicine. Formulary committees
must make recommendations when there is incom-
plete information available to answer the three
questions stated above. To deal with this inherent
uncertainty, formularies follow a decision logic that
attempts to limit uncertainty through simplifying 
assumptions.
Commonly, formulary committees start by
asking the question—does the new therapy repre-
sent a new “class” of drugs or is it a member of 
an existing therapeutic class? If the drugs are in the
same class, they are presumed to be interchangeable
since they have closely related pharmacology, ther-
apeutic activity, and adverse reactions—that is,
there is a presumption of comparability of risk-
beneﬁt proﬁles. This presumption allows rational
formulary designs that employ “preferred agents”
or “tiered copays” since —all other things being
equal—selection of a less expensive therapeutic
agent for preferred status enhances the ability of a
managed care organization to maximize the provi-
sion of health services to its members. In pharma-
coeconomic terms, it facilitates a cost-minimization
approach to drugs within a therapeutic class; a cost-
effectiveness analysis may be utilized when drugs
within a class exhibit different proﬁles with respect
to biomarkers or surrogate end points with the
assumption that these are the only important dif-
ferences in their risk-beneﬁt proﬁles—that is, they
are otherwise interchangeable. Here we use the
terms biomarkers and surrogate end points as
deﬁned by the Biomarkers Working Group: bio-
markers are objectively measured indicators of 
biologic processes, pathogenetic processes, or 
pharmacologic responses to therapeutic interven-
tions (e.g., blood cholesterol, CEA levels); surrogate
end points are biomarkers that are expected to
predict clinical beneﬁt or harms based on epidemi-
ologic, therapeutic, pathophysiologic, or other 
scientiﬁc evidence (e.g., blood pressure, LDL 
cholesterol) [4].
Drugs from different therapeutic classes are pre-
sumed not be interchangeable. Thus separate atten-
tion must be paid to the individual proﬁle of
beneﬁts, risks, and costs for drugs being compared.
In this situation, the comparison often rapidly
focuses on relative effectiveness. If the ﬁrst drug in
a new class provides signiﬁcantly greater beneﬁt in
comparison to existing therapy, it will be added to
the formulary. This is generally followed by a more
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extended discussion to determine whether and to
what extent access should be limited—either
because of perceived ﬁnancial impact or because 
the new drug has a signiﬁcantly different balance 
of beneﬁts and risks for speciﬁc subpopulations of
patients.
However, as Furberg et al. and others [5–7] have
argued, there is no established clinical or scientiﬁc
deﬁnition of a therapeutic drug class. While the
grouping of drugs into a class is generally based on
a common mechanism of action (reﬂected by their
impact on speciﬁc biomarkers or surrogate end
points), all drugs exhibit multiple effects determined
by their unique chemical structures. There are
important differences in clinical beneﬁts and risks
within a drug class and one can be led astray by too
great a reliance on surrogate end points [8–10].
DeMets and Califf [9] have reviewed the dramatic
failure of the surrogate endpoint of suppression of
premature ventricular contractions as a predictor of
survival in the Cardiac Arrythmia Suppression Trial
(CAST). They elegantly describe the limits to the
validity of other surrogate end points such as blood
pressure and LDL cholesterol levels based upon the
results of various of recent large randomized con-
trolled clinical trials including the Antihypertensive
and Lipid Lowering Treatment to Prevent Heart
Attack Trial (ALLHAT). They also note that the
product recall of cerivastatin occurred within a
context of a known risk of rhabdomyolsis in the
absence of quantiﬁcation of clinical beneﬁt.
We should strongly reconsider the blanket use 
of the concept of therapeutic class as a simplifying
assumption by formulary committees. Perhaps
greater consideration should be given to drugs with
end point outcome data and/or extensive drug expe-
rience. Certainly, that was the recent recommenda-
tion from Oregon Health and Science University’s
Evidence-Based Practice Center in their review of
HMGs for Oregon Medicaid [11]. Formulary com-
mittees should also require stronger information
regarding effectiveness and/or safety from new
entrants into an established class, especially if the
class has been available for a substantial length of
time.
There has been much concern among payers 
and managed care organizations that “me-too”
drugs are not valuable—because in their opinion
they neither provide substantial efﬁcacy advantages
as measured by biomarkers or surrogate end points,
nor do they provide substantial decreases in drug
acquisition costs. This view not only discounts the
value that new entrants may bring in terms of con-
venience and adherence as a result of new dosing
regimens or formulations, but also reinforces the
current dynamics of the marketplace for pharma-
ceutical research and development. A policy of 
preference for drugs with proven outcomes and
established tolerability would be a powerful incen-
tive for manufacturers to develop and provide end
point outcomes data as part of the launching a third
or fourth entrant in an established drug class. While
such a preference would neither be desirable or fea-
sible with respect to the launch of the ﬁrst entrant
in a new class, a general preference for drugs with
proven outcomes would also serve as a powerful
incentive for manufacturers to expeditiously com-
plete endpoint clinical trials—lest that subsequent
class entrants supply end point data, reaping the
preference beneﬁt. If our recent experience means
anything, we need much more data from end point
clinical trials for providers to have the information
necessary to truly practice evidence-based medicine.
Shouldn’t it be worth it?–Marc L. Berger, M.D.,
Vice President, USHH Outcomes Research & 
Management, Merck & Co., Inc.
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